Moderna Impfstoff (Spikevax) — the Moderna vaccine — has gone from an emergency fix to a long?term tool for living with COVID. If you’re wondering whether this mRNA shot still matters in 2026, here’s ...
Moderna, Inc. (MRNA) on Thursday announced that the U.S. Food and Drug Administration (FDA) has fully approved its COVID-19 vaccine Spikevax in children aged six months through 11 years who are at ...
mFLUSIVA becomes Moderna's fifth approved product globally and fourth FDA-approved product Company expects supply to be available ... · ACCESS Newswire · Moderna, Inc. The above button links to ...
Real-world analysis of more than 294,000 U.S. Veterans aged 65 and older found mNEXSPIKE was associated with a 35.9% ...
Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of Spikevax, which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. The ...
CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...
Spikevax, Moderna's mRNA COVID-19 vaccine, delivers strong protection against severe disease through innovative technology accessible worldwide. MRNA, US60770K1079, Illustration mit AI erstellt.
Add Yahoo as a preferred source to see more of our stories on Google. A Moderna COVID-19 vaccine (brand name: Spikevax) photographed at Borinquen Health Care Center on May 29 in Miami. (Photo ...
"Today, we are reiterating our signed advanced purchase agreements for 2022 of $21 billion," said CEO Stéphane Bancel.
Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...